VKTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
187.1M
+41.1%
132.6M
-19.2%
164.1M
-0.4%
164.7M
+67.1%
98.6M
R&D
166.8M
+44.1%
115.8M
-22.9%
150.2M
-2.2%
153.5M
+70.6%
90.0M
SG&A
20.3M
+20.6%
16.8M
+20.5%
14.0M
+23.9%
11.3M
+31.0%
8.6M
Operating Income
-187112000
-41.1%
-132597000
+19.2%
-164125000
+0.4%
-164738000
-67.1%
-98561000
EBITDA
-187112000
-41.1%
-132597000
+19.2%
-164125000
+0.4%
-164738000
-67.1%
-98561000
Net Income
-183186000
-43.1%
-128022000
+19.1%
-158325000
-0.4%
-157662000
-73.7%
-90787000
EPS (Basic)
$-1.55
-40.9%
$-1.10
+19.7%
$-1.37
+0.7%
$-1.38
-70.4%
$-0.81
EPS (Diluted)
$-1.55
-40.9%
$-1.10
+19.7%
$-1.37
+0.7%
$-1.38
-70.4%
$-0.81
Shares (Diluted)
118.0M
+1.5%
116.3M
+0.6%
115.6M
+1.2%
114.1M
+1.6%
112.3M
Viking Therapeutics (VKTX) — Financials